Ms. Androski joined Arbutus in February 2025 as President and CEO and Chairperson of the Board. Ms. Androski, an MIT-trained biologist, has nearly 30 years of experience in biotechnology, law, and academia. She also currently serves as Special Counsel at Genevant Sciences and has previously served in a variety of roles at Roivant, including Vice President, Head of Acquisitions and CEO of Roivant Social Ventures. At Roivant she built and led the team responsible for the in-licensing or acquisition of more than 30 therapeutic programs, resulting in the launch and incubation of 16 subsidiary biotechs and several successful IPOs. Prior to joining Roivant, Ms. Androski spent more than a decade as a trial lawyer, including as an Assistant U.S. Attorney in the Eastern District of Virginia. Earlier in her career, Ms. Androski was a strategy consultant advising Fortune 100 clients on merger integration and other business challenges. Ms. Androski holds two Bachelor of Science degrees from the Massachusetts Institute of Technology, JD and MBA degrees from The University of Chicago, is a registered Patent Lawyer and a CFA charterholder. She Chairs the MIT Press Advisory Board, sits on the MIT HEALS (Health and Life Sciences) Advisory Board, and previously served as a Trustee of MIT and as Chair of the Visiting Committee for the Department of Chemistry.

Tags